PMID- 36248798
OWN - NLM
STAT- MEDLINE
DCOM- 20221018
LR  - 20221020
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Downregulation of long noncoding RNA HCP5/miR-216a-5p/ZEB1 axis inhibits the 
      malignant biological function of laryngeal squamous cell carcinoma cells.
PG  - 1022677
LID - 10.3389/fimmu.2022.1022677 [doi]
LID - 1022677
AB  - Previous studies find that long noncoding RNA human leukocyte antigen complex P5 
      (HCP5) is regarded as an oncogene via accelerating cancer cell growth, invasion, 
      metastasis, vascularization, and drug resistance in renal cell carcinoma, gastric 
      cancer, and colorectal cancer. Nevertheless, the effect and regulatory mechanism 
      of HCP5 in laryngeal squamous cell carcinoma (LSCC) remains unknown. In this 
      study, HCP5 expression levels were confirmed to be prominently raised in LSCC 
      cell lines. HCP5 knockdown reduced cell proliferation and migration and invasive 
      ability of LSCC cell lines. Furthermore, miR-216a-5p was confirmed to sponge 
      HCP5, and its expression was prominently downregulated in LSCC cell lines and 
      upregulated in HCP5-silenced LSCC cell lines. miR-216a-5p overexpression 
      downregulated the cell proliferation and migration and invasive ability of LSCC 
      cells. Additionally, the protein level of zinc finger E-box binding homeobox 1 
      (ZEB1), one target gene of miR-216a-5p, was highly expressed in LSCC cell lines, 
      and its expression level was downregulated by HCP5 knockdown and miR-216a-5p 
      overexpression. An miR-216a-5p inhibitor reversed the effect of HCP5 knockdown on 
      the proliferation and migration and invasive ability of LSCC cells. In 
      conclusion, knocking down HCP5 may be a strategy to suppress the malignant 
      biological function via regulating miR-216a-5p/ZEB1. Therefore, HCP5 may become a 
      prospective therapeutic target for LSCC.
CI  - Copyright (c) 2022 Zhang, Huangfu, Zhao, Li and Wu.
FAU - Zhang, Sen
AU  - Zhang S
AD  - Department of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi 
      Medical University, Taiyuan, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, China.
FAU - Huangfu, Hui
AU  - Huangfu H
AD  - Department of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi 
      Medical University, Taiyuan, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, China.
FAU - Zhao, Qinli
AU  - Zhao Q
AD  - Department of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi 
      Medical University, Taiyuan, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, China.
FAU - Li, Yujun
AU  - Li Y
AD  - Department of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi 
      Medical University, Taiyuan, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical 
      University, Taiyuan, China.
FAU - Wu, Lina
AU  - Wu L
AD  - Department of Pathology, The First Hospital, Shanxi Medical University, Taiyuan, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220930
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA Antigens)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (ZEB1 protein, human)
RN  - 0 (Zinc Finger E-box-Binding Homeobox 1)
SB  - IM
MH  - Cell Line, Tumor
MH  - Down-Regulation
MH  - Gene Expression Regulation, Neoplastic
MH  - HLA Antigens
MH  - *Head and Neck Neoplasms/genetics
MH  - Humans
MH  - *MicroRNAs/genetics/metabolism
MH  - *RNA, Long Noncoding/metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
MH  - Zinc Finger E-box-Binding Homeobox 1/genetics/metabolism
PMC - PMC9561619
OTO - NOTNLM
OT  - ZEB1
OT  - invasion
OT  - lncRNA
OT  - miRNA
OT  - migration
OT  - proliferation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/19 06:00
PMCR- 2022/01/01
CRDT- 2022/10/17 05:13
PHST- 2022/08/18 00:00 [received]
PHST- 2022/09/06 00:00 [accepted]
PHST- 2022/10/17 05:13 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/19 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1022677 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 30;13:1022677. doi: 10.3389/fimmu.2022.1022677. 
      eCollection 2022.